Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction Notification

Description of Procedure or Service

Nasal obstruction is defined clinically as an individual’s symptom that presents as a sensation of reduced or insufficient airflow through the nose. Nasal valve collapse (NVC) is a readily identifiable cause of nasal obstruction. Specifically, the internal nasal valve represents the narrowest portion of the nasal airway with the upper lateral nasal cartilages present as supporting structures. The external nasal valve is an area of potential dynamic collapse that is supported by the lower lateral cartilages. Damaged or weakened cartilage will further decrease airway capacity and increase airflow resistance and may be associated with symptoms of obstruction. Individuals with NVC may be treated with nonsurgical interventions in an attempt to increase the airway capacity but severe symptoms and anatomic distortion are treated with surgical cartilage graft procedures. The application of radiofrequency (RF) volumetric tissue reduction for nasal obstruction has been proposed as a less invasive means to treat nasal obstruction due to internal NVC. By utilizing RF energy, the treatment aims to provide relief with reduced recovery times and fewer complications compared to traditional surgical methods.

Nasal Obstruction

Nasal obstruction is a clinical symptom marked by the sensation of diminished airflow through the nose.  Commonly, individuals will feel that they have nasal congestion or stuffiness.  In adults, clinicians focus on the evaluation of important features of the history provided by the individual such as whether symptoms are unilateral or bilateral. Unilateral symptoms are more suggestive of structural causes of nasal obstruction. A history of trauma or previous nasal surgery, especially septoplasty or rhinoplasty, is also important. Diurnal or seasonal variation in symptoms is associated with allergic conditions. Nasal valve collapse (NVC) is a is a readily identifiable cause of nasal obstruction.

The internal nasal valve is the narrowest part of the nasal passage and is supported by the upper lateral nasal cartilages (see pathophysiology below). On the other hand, the external nasal valve, also known as the nasal entrance, is prone to dynamic collapse and is supported by the lower lateral cartilages. When cartilage is damaged or weakened, it can reduce airway capacity, increase airflow resistance, and lead to symptoms of obstruction.  While nonsurgical treatments aim to enhance airway capacity in individuals with NVC, severe symptoms and significant anatomical distortion typically require surgical cartilage graft procedures.

Etiology

Nasal obstruction associated with the external nasal valve is commonly associated with post-rhinoplasty or traumatic sequelae and may require functional rhinoplasty procedures. A common cause of internal nasal valve collapse is a septal deviation. Prior nasal surgery, nasal trauma, and congenital anomaly are additional causes.

Pathophysiology

The internal nasal valve, bordered by the collapsible soft tissue between the upper and lower lateral cartilages, the anterior end of the inferior turbinate, and the nasal septum, forms the narrowest part of the nasal airway.  During inspiration, the lateral wall cartilage is dynamic and draws inward toward the septum and the internal nasal valve narrows providing protection to the upper airways. Given that the internal nasal valve accounts for at least half of the nasal airway resistance; even minor further narrowing of this area can lead to symptomatic obstruction for an individual. Damaged or weakened lateral nasal cartilage will further decrease airway capacity of the internal nasal valve area, increasing airflow resistance and symptoms of congestion.

Physical Examination

A thorough physical examination of the nose, nasal cavity, and nasopharynx is generally sufficient to identify the most likely etiology for the nasal obstruction. Both the external and internal nasal valve areas should be examined. The external nasal valve is at the level of the internal nostril. It is formed by the caudal portion of the lower lateral cartilage, surrounding soft tissue, and the membranous septum.

The Cottle maneuver is an examination in which the cheek on the symptomatic side is gently pulled laterally with 1 to 2 fingers. If the individual is less symptomatic with inspiration during the maneuver, the assumption is that the nasal valve has been widened from a collapsed state or dynamic nasal valve collapse. An individual can perform the maneuver on oneself, and it is subjective. A clinician performs the modified Cottle maneuver. A cotton swab or curette is inserted into the nasal cavity to support the nasal cartilage and the individual reports whether there is an improvement in the symptoms with inspiration. In both instances, a change in the external contour of the lateral nose may be apparent to both the individual and the examiner.

According to American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS, 2023):

• "The diagnosis of symptomatic nasal valve dysfunction is a clinical diagnosis, made by patient history and physical exam. These diagnoses are made by a qualified Otolaryngologist as a part of a thorough physical examination of the nose...Subjective improvement in nasal breathing with the Cottle or modified Cottle maneuver confirms the diagnosis of nasal valve collapse."

Treatment

Treatment of symptomatic nasal valve collapse includes the use of non-surgical interventions such as the adhesive strips applied externally across the nose or use of nasal dilators, cones, or other devices that support the lateral nasal wall internally applying the principle of the modified Cottle maneuver. Severe cases of obstruction resulting from nasal valve deformities are treated with surgical grafting to widen and/or strengthen the valve. Common materials include cartilaginous autografts and allografts, as well as permanent synthetic grafts. Cartilage grafts are most commonly harvested from the individual’s nasal septum or ear.

Radiofrequency Volumetric Tissue Reduction

The application of low-dose radiofrequency (RF) energy has been proposed as an alternative technique for reshaping nasal tissue to address NVC. This method has been suggested as a viable alternative to more invasive grafting procedures, particularly for individuals experiencing severe nasal obstruction. By utilizing RF energy, the treatment aims to provide relief with reduced recovery times and fewer complications compared to traditional surgical methods.

Regulatory Status

In April 2020, the VivAer® Stylus (Aerin Medical) was cleared for use in otorhinolaryngology (ENT) surgery by the FDA through the 510(k) process as a tool to treat nasal obstruction (K200300).  Clearance was based on equivalence in design and intended use of a predicate device, the VivAer® ARC Stylus (K172529). The VivAer® Stylus is functionally unchanged from the predicate in design and intended use to generate and deliver bipolar RF energy to treat tissue in otorhinolaryngology (ENT) procedures. As per the FDA 510Ksummary, the VivAer® Stylus is indicated for use in ENT surgery for the coagulation of soft tissue in the nasal airway, to treat nasal airway obstruction by shrinking submucosal tissue, including cartilage in the internal nasal valve area.

The VivAer® Stylus is distinct from the RhinAer® device (Aerin Medical) currently reviewed in the Cryoablation, Radiofrequency Ablation, and Laser Ablation for Treatment of Chronic Rhinitis medical policy as it targets nasal tissue for remodeling to improve airflow as opposed to disrupting the posterior nasal nerve in rhinitis.

Related Policies:

Absorbable Nasal Implant for Treatment of Nasal Valve Collapse

Balloon Ostial Dilation (Balloon Sinuplasty)

Cryoablation, Radiofrequency Ablation, and Laser Ablation for Treatment of Chronic Rhinitis

Surgical Treatment of Sinus Disease

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction is considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction is covered

Not applicable

When Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction is not covered

Radiofrequency volumetric tissue reduction for nasal obstruction due to internal nasal valve collapse is considered investigational.

Policy Guidelines

For individuals with symptomatic nasal obstruction due to internal nasal valve collapse who receive radiofrequency volumetric tissue reduction (RFVTR), the evidence includes systematic reviews and a randomized controlled trial (RCT) with 12-month and 24-month uncontrolled follow-up phases. Relevant outcomes are symptoms, change in disease status, treatment-related morbidity, functional outcomes, and quality of life. Systematic reviews have generally shown improvements in nasal obstruction scores. In the RCT, follow-up at 3 months revealed a statistically significant improvement in response with the RFVTR procedure compared to the sham group. However, these results are limited by the small study size, lack of diversity, short duration, and failure to control confounding factors such as medication or nasal dilator use. Moreover, the trial's results may not fully represent the potential effect of RFVTR since treatment was limited to lateral nasal wall repair, not addressing soft tissues like septal swell bodies and inferior turbinates. A significant and durable effect on nasal obstruction post-RFVTR treatment was reported up to 36 months during the uncontrolled crossover phase of the trial. Additional RCTs with extended follow-up periods, larger and more diverse populations, and comparisons of RFVTR to other treatments (medications, nasal dilators, and rhinoplasty) are necessary to confirm the procedure's efficacy for nasal obstruction. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 30469

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

Lee DY, Won TB. Management of Nasal Valve Dysfunction. Clin Exp Otorhinolaryngol. Aug 2024; 17(3):189-197. PMID 39111772

Wang Y, Bonaparte JP. Diagnosis and management of septal deviation and nasal valve collapse – a survey of Canadian otolaryngologists. J Otolaryngol Head Neck Surg. Dec 16 2019; 48(1): 71. PMID31842991

American Academy of Otolaryngology-Head and Neck Surgery. Position Statement: Nasal Valve Repair,2023; https://www.entnet.org/resource/position-statement-nasal-valve-repair/. Accessed December 18,2025.

Food & Drug Administration. VivAer Stylus 510(k) Premarket Notification. 2020 (K200300). https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200300.pdf. Accessed December 18, 2025.

Casale M, Moffa A, Giorgi L, et al. Could the use of a new novel bipolar radiofrequency device (Aerin)improve nasal valve collapse? A systematic review and meta-analysis. J Otolaryngol Head Neck Surg. Jun 22 2023; 52(1): 42. PMID 37349806

Han JK, Perkins J, Lerner D, et al. Comparison of nasal valve dysfunction treatment outcomes for temperature-controlled radiofrequency and functional rhinoplasty surgery: a systematic review and meta-analyses. Rhinology. Jun 01 2024; 62(3): 258-270. PMID 38217624

Kang YJ, Kim DH, Stybayeva G, et al. Effectiveness of Radiofrequency Device Treatment for NasalValve Collapse in Patients With Nasal Obstruction. Otolaryngol Head Neck Surg. Jan 2024; 170(1): 34-44. PMID 37702187

Silvers SL, Rosenthal JN, McDuffie CM, et al. Temperature-controlled radiofrequency device treatment of the nasal valve for nasal airway obstruction: A randomized controlled trial. Int Forum Allergy Rhinol. Dec 2021; 11(12): 1676-1684. PMID 34240571

Han JK, Silvers SL, Rosenthal JN, et al. Outcomes 12 Months After Temperature-Controlled Radiofrequency Device Treatment of the Nasal Valve for Patients With Nasal Airway Obstruction. JAMA Otolaryngol Head Neck Surg. Oct 01 2022; 148(10): 940-946. PMID 36048465

Silvers SL, McDuffie CM, Yen DM, et al. Two-year outcomes of radiofrequency device treatment of the nasal valve for nasal airway obstruction. Rhinology. Jun 01 2024; 62(3): 310-319. PMID 38217847

Han JK, Rosenthal JN, McDuffie CM, et al. Temperature-Controlled Radiofrequency Treatment of the Nasal Valve in Patients With Nasal Obstruction: Long-Term Outcomes. Otolaryngol Head Neck Surg. Apr 2025; 172(4): 1214-1223. PMID 39822054

Medical Director Review 8/2026

Specialty Matched Consultant Advisory Panel 8/2026

Policy Implementation/Update Information

9/9/26 New policy developed.  Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction is considered investigational. Notification given 9/9/2026 for policy effective date 11/18/2026. (ldh)